ASTRAZENECA GOSERELIN goserelin 3.6mg (as acetate) implant syringe

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

goserelin, Quantity: 3.6 mg

Available from:

AstraZeneca Pty Ltd

INN (International Name):

Goserelin

Pharmaceutical form:

Implant

Composition:

Excipient Ingredients: polyglactin

Administration route:

Subcutaneous

Units in package:

single syringe

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Prostate Cancer: Palliative treatment of metastatic or locally advanced prostate cancer, where suitable for hormonal manipulation. Adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. Breast Cancer: Treatment of advanced breast cancer (T3b, T4 or any T with N2, 3 or M plus) in premenopausal women suitable for hormonal manipulation. Adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. Endometriosis: In the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. Uterine Fibroids: In the management of fibroids, ASTRAZENECA GOSERELIN shrinks the lesions and reduces the symptoms, including pain. ASTRAZENECA GOSERELIN also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. It is used as an adjunct to surgery to facilitate the operative technique and reduce operativeblood loss. Endometrial Thinning: Use as an endometrial thinning agent prior to endometrial ablation. Assisted Reproduction: Pituitary down regulation in preparation for controlled ovarian superstimulation.

Product summary:

Visual Identification: White to cream-coloured cylindrical pieces of rigid polymeric material.; Container Type: Syringe; Container Material: Plastic; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Registered

Authorization date:

2006-08-15